Bharat Biotech’s indigenous Corona vaccine ‘Kovaxine’ has shown better immune response in the first phase of clinical trials. No side effects of this vaccine have been seen during the trial. Interim results of the first phase of clinical trials have shown that no serious or adverse effects have been observed on all age groups. In the foreign portal ‘MedRxIV’, it has been claimed that the vaccine is completely safe and effective. The first phase of clinical trial of this biotech of India biotech ended in September itself, the results of which have now been made public.
The year 2020 is nearing its end and with this some positive news has started coming in the ongoing war against the corona virus. Interim results of the first stage clinical trial of the indigenous covid-19 vaccine ‘Kovaxin’ developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) showed no serious or adverse effects on all age groups.
According to the result, ‘a serious case of adverse effect came up. The participant was given a vaccine dose on 30 July. Five days later, the symptoms of covid-19 were found in the patient and he was found infected with SARS-Cov 2. It says, ‘These were mild symptoms but the patient was admitted to the hospital on 15 August. The patient was discharged from the hospital on August 22 after the nucleic acid results were negative. This case was not associated with the vaccine.
In order to test it, 375 volunteers were involved at different places in 11 hospitals.